ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 157 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,913 | +635.8% | 1,156 | +1309.8% | 0.00% | – |
| Q2 2023 | $1,755 | -88.2% | 82 | -77.8% | 0.00% | -100.0% |
| Q1 2023 | $14,923 | -20.8% | 369 | -8.9% | 0.00% | 0.0% |
| Q4 2022 | $18,841 | +34.6% | 405 | +47.8% | 0.00% | 0.0% |
| Q3 2022 | $14,000 | +55.6% | 274 | +44.2% | 0.00% | +100.0% |
| Q2 2022 | $9,000 | -30.8% | 190 | +6.7% | 0.00% | -50.0% |
| Q1 2022 | $13,000 | +8.3% | 178 | +8.5% | 0.00% | +100.0% |
| Q4 2021 | $12,000 | +9.1% | 164 | -13.7% | 0.00% | -50.0% |
| Q3 2021 | $11,000 | +37.5% | 190 | +9.2% | 0.00% | +100.0% |
| Q2 2021 | $8,000 | -20.0% | 174 | -10.8% | 0.00% | -50.0% |
| Q1 2021 | $10,000 | +42.9% | 195 | +18.2% | 0.00% | +100.0% |
| Q4 2020 | $7,000 | +133.3% | 165 | +120.0% | 0.00% | 0.0% |
| Q3 2020 | $3,000 | +50.0% | 75 | +78.6% | 0.00% | – |
| Q2 2020 | $2,000 | -92.9% | 42 | -92.1% | 0.00% | -100.0% |
| Q1 2020 | $28,000 | +1300.0% | 533 | +1169.0% | 0.01% | – |
| Q4 2019 | $2,000 | 0.0% | 42 | 0.0% | 0.00% | – |
| Q3 2019 | $2,000 | -33.3% | 42 | 0.0% | 0.00% | – |
| Q2 2019 | $3,000 | -25.0% | 42 | 0.0% | 0.00% | -100.0% |
| Q1 2019 | $4,000 | +100.0% | 42 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $2,000 | -33.3% | 42 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $3,000 | -25.0% | 42 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $4,000 | +33.3% | 42 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $3,000 | +50.0% | 42 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $2,000 | +100.0% | 42 | 0.0% | 0.00% | – |
| Q3 2017 | $1,000 | – | 42 | 0.0% | 0.00% | – |
| Q2 2017 | $0 | -100.0% | 42 | 0.0% | 0.00% | – |
| Q1 2017 | $1,000 | 0.0% | 42 | 0.0% | 0.00% | -100.0% |
| Q4 2016 | $1,000 | 0.0% | 42 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $1,000 | – | 42 | +68.0% | 0.00% | – |
| Q4 2015 | $0 | -100.0% | 25 | -75.5% | 0.00% | -100.0% |
| Q3 2015 | $2,000 | -50.0% | 102 | 0.0% | 0.00% | -66.7% |
| Q2 2015 | $4,000 | – | 102 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |